Corix Bioscience (Corix Bioscience) Debt-to-Equity : 0.01 (As of Sep. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience Debt-to-Equity?

Corix Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.05 Mil. Corix Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Corix Bioscience's Total Stockholders Equity for the quarter that ended in Sep. 2017 was $3.56 Mil. Corix Bioscience's debt to equity for the quarter that ended in Sep. 2017 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Corix Bioscience's Debt-to-Equity or its related term are showing as below:

CXBS's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Corix Bioscience Debt-to-Equity Historical Data

The historical data trend for Corix Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corix Bioscience Debt-to-Equity Chart

Corix Bioscience Annual Data

Trend

Jan09

Jan10

Jan11

Jan12

Jan13

Jan14

Jan15

Dec16

Debt-to-Equity

Get a 7-Day Free Trial

-0.47

-0.22

1.15

Corix Bioscience Quarterly Data
	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Debt-to-Equity	Get a 7-Day Free Trial															1.21	1.15	N/A	-	0.01

Competitive Comparison of Corix Bioscience's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Debt-to-Equity falls into.

Corix Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Corix Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.074	+	5.077)	/	4.476
	=	1.15

Corix Bioscience's Debt to Equity Ratio for the quarter that ended in Sep. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.05	+	0)	/	3.558
	=	0.01

Corix Bioscience (GREY:CXBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Corix Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Corix Bioscience (Corix Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085

Website

http://www.corixbioscience.com

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines